5-year results of a newly implemented mechanical circulatory support program for terminal heart failure patients in a Swiss non-cardiac transplant university hospital

Table 3 Comparison of internationally reported overall survival and freedom from major adverse events after LVAD-Implantation

Outcome	USB		INTERMACS 2017^a		EUROMACS 2018		STS 2019^b
Outcome	1 year	2 years	1 year	2 years	1 year	2 years	1 year	2 years
Overall survival	87.5%	70%	84%	74%	69%	55%	81%	72%
Freedom from stroke	81.3%	81.3%	86%	82%	NR	NR	83%	80%
Freedom from device infection	67.7%	58.7%	86%	80%	NR	NR	60%	49%
Freedom from gastrointestinal bleeding	75%	56.3%	NR	NR	NR	NR	80%	75%

LVAD left-ventricular assist device, USB University Hospital of Basel, INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support, EUROMCAS European Registry for Patients with Mechanical Circulatory Support, STS Society of Thoracic Surgeons, NR not reported
^apatients with specifically high INTERMACS profiles (4–7)
^bpatients after implantation of continuous-flow hybrid levitation devices

ISSN: 1749-8090